Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

With 16 IDEs Approved, FDA Still Questions Artificial Pancreas Study Designs

This article was originally published in The Gray Sheet

Executive Summary

Since 2003, FDA has approved 16 investigational device exemptions for companies to begin trials on "artificial pancreas" devices, yet the agency is questioning what constitutes an appropriate study design for the products.

You may also be interested in...



Diabetes Researchers Say FDA Is Slowing Artificial Pancreas Efforts

Developers of "artificial pancreas" devices for treating type 1 diabetes may gain insight from new FDA draft guidance on clinical trial design, but patients and advocates say the agency is standing in the way of greater advances in the space.

Diabetes Researchers Say FDA Is Slowing Artificial Pancreas Efforts

The U.S. is "desperately behind the curve," as a "result of regulatory policy that is just not working in the interest of people who live with type 1 diabetes," JDRF CEO says.

Diabetes Researchers Say FDA Is Slowing Artificial Pancreas Efforts

Developers of "artificial pancreas" devices for treating type 1 diabetes may gain insight from new FDA draft guidance on clinical trial design, but patients and advocates say the agency is standing in the way of greater advances in the space.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT029623

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel